TY - JOUR T1 - Extracorporeal Photopheresis in Pediatric Graft-vs-Host Disease JO - Actas Dermo-Sifiliográficas T2 - AU - Cueto Sarmiento,K.Y. AU - Baquero Rey,J.A. AU - Andrade Miranda,A. AU - Bruey,S.A. AU - Makiya,M.L. AU - Mazzuoccolo,L.D. AU - Enz,P.A. SN - 15782190 M3 - 10.1016/j.adengl.2021.05.017 DO - 10.1016/j.adengl.2021.05.017 UR - https://actasdermo.org/en-extracorporeal-photopheresis-in-pediatric-graft-vs-host-articulo-S1578219021001773 AB - BackgroundExtracorporeal photopheresis (ECP) is an immunomodulatory therapy used to treat graft-vs-host disease (GVHD) in adults and children. Few studies have examined its use in children. ObjectiveTo describe demographic characteristics, clinical response, adverse effects, and outcomes in a series of pediatric patients with acute or chronic GVHD treated with ECP. Material and methodsWe included all pediatric patients with acute or chronic GVHD treated with ECP by the dermatology department of Hospital Italiano de Buenos Aires between January 2012 and December 2018. We used the UVAR-XTS™ system (2 patients) and the CELLEX system (7 patients). Patients with acute GVHD received 2 sessions a week and were reassessed at 1 month, while those with chronic GVHD received 2 sessions every 2 weeks and were reassessed at 3 months. Treatment duration in both scenarios varied according to response. ResultsWe evaluated 9 pediatric patients with corticosteroid-refractory, -dependent, and/or -resistant GVHD treated with ECP. Seven responded to treatment and 2 did not. Response was complete in 1 of the 9 patients with skin involvement and partial in 7. Complete response rates for the other sites of involvement were 60% (3/5) for the liver, 50% (1/2) for the gastrointestinal system, and 80% (4/5) for mucous membranes. Two patients died during the study period. ConclusionECP is a good treatment option for pediatric patients with acute or chronic GVHD. ER -